West Pharma Q2 FY26 EPS rises 18.1% to $2.15; net sales increase 13.8% to $872.3 million

• West Pharmaceutical Services posted Q2 2026 net sales of $872.3 million, up 13.8% from a year earlier; GAAP diluted EPS rose 18.1% to $2.15.
• GAAP net income climbed to $154 million; GAAP operating profit increased to $179.1 million.
• Proprietary Products net sales rose 16.6% to $722.6 million, led by HVP Components up 19.4% to $424.1 million.
• Operating cash flow was $213.9 million; capital expenditures were $85.9 million.
• Full-year net sales guidance was raised to $3.345 billion-$3.38 billion; adjusted-diluted EPS guidance increased to $8.85-$9.05.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. West Pharmaceutical Services Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202607230600PR_NEWS_USPR_____NE10613) on July 23, 2026, and is solely responsible for the information contained therein.